Following the breakthrough in the drug being developed by US developers Pfizer and BioNTech, who stated their own vaccine was 90 percent effective, Russia has now pushed the effectiveness of their own drug. The results of the Sputnik V drug has come from the first 16,000 trial participants, from the Russian Direct Investment Fund (RDIF). The Sputnik V drug is being developed by the Gamaleya Institute who has included 40,000 volunteers in its trials.
The Russian drug was the first to be registered in the world in August and has sparked a race to create a large-scale drug to stop the coronavirus pandemic.
Russian Direct Investment Fund (RDIF) head Kirill Dmitriev said: “We are showing, based on the data, that we have a very effective vaccine.”
Amid the breakthrough in the drug, Turkey has voiced its interest in producing the drugs at its facilities.
The Russian Health Ministry said: “The sides discussed the situation with the novel coronavirus infection’s spread and especially focused on the issues of developing vaccines for preventing COVID-19.
“The Turkish health minister expressed interest in launching Sputnik V vaccine’s production at the facilities of Turkish pharmaceutical manufacturers after carrying out toxicological studies envisaged by local legislation.”
Russia has stated 20 countries have already applied to receive the drug from the RDIF.
This week, Pfizer and BioNTech announced the results of the trials of its drug.
Due to this, there is now the hope the UK could receive a limited supply of the vaccine by Christmas.
JUST IN: Brexit LIVE: Huge US trade deal warning after Biden phone call
“There’s a long way I am afraid before we have got this thing beaten.”
The UK currently has six vaccines secured: from AstraZeneca and the University of Oxford, BioNTech and Pfizer, Janssen, Novavax, and by GSK and Sanofi, and one from Valneva which will not be ready until 2021.
Although the Pfizer’s results were a welcome boost for the Government, the drug from Oxford University is thought to be the front runner for the UK.
Not only does the UK have 100 million doses of the drug but due to it being produced in Britain, it would be cheaper.
Like Pfizer, the drug is currently going through Phase 3 trials before being approved.
Health Secretary, Matt Hancock also stated there are more logistical problems involved with the Pfizer drug.
He said: “You can’t take it out of that freezer more than four times on its journey from the manufacturing plant into the arms of patients so that brings its complications.
“The AstraZeneca vaccine is easier to deploy logistically.”